JP2015526458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526458A5 JP2015526458A5 JP2015527922A JP2015527922A JP2015526458A5 JP 2015526458 A5 JP2015526458 A5 JP 2015526458A5 JP 2015527922 A JP2015527922 A JP 2015527922A JP 2015527922 A JP2015527922 A JP 2015527922A JP 2015526458 A5 JP2015526458 A5 JP 2015526458A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nep inhibitor
- delay
- prevention
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 206010019280 Heart failures Diseases 0.000 claims description 15
- 230000001746 atrial effect Effects 0.000 claims description 15
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 238000007634 remodeling Methods 0.000 claims description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 7
- 229960004699 valsartan Drugs 0.000 claims description 7
- 102400001263 NT-proBNP Human genes 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 4
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 5
- HCRBXQFHJMCTLF-UHFFFAOYSA-N ethyl 2-methylbutyrate Chemical compound CCOC(=O)C(C)CC HCRBXQFHJMCTLF-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 77
- 229940002612 prodrug Drugs 0.000 description 40
- 239000000651 prodrug Substances 0.000 description 40
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 3
- 208000008253 Systolic Heart Failure Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AEBRINKRALSWNY-SCSAIBSYSA-N (2r)-4-amino-2-methylbutanoic acid Chemical compound OC(=O)[C@H](C)CCN AEBRINKRALSWNY-SCSAIBSYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018228452A JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692911P | 2012-08-24 | 2012-08-24 | |
| US61/692,911 | 2012-08-24 | ||
| PCT/EP2013/067472 WO2014029848A1 (en) | 2012-08-24 | 2013-08-22 | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228452A Division JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526458A JP2015526458A (ja) | 2015-09-10 |
| JP2015526458A5 true JP2015526458A5 (enExample) | 2016-11-24 |
| JP6482462B2 JP6482462B2 (ja) | 2019-03-13 |
Family
ID=49000959
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527922A Active JP6482462B2 (ja) | 2012-08-24 | 2013-08-22 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2018228452A Active JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2021155220A Pending JP2022020624A (ja) | 2012-08-24 | 2021-09-24 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2023124147A Withdrawn JP2023159114A (ja) | 2012-08-24 | 2023-07-31 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018228452A Active JP7407508B2 (ja) | 2012-08-24 | 2018-12-05 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2021155220A Pending JP2022020624A (ja) | 2012-08-24 | 2021-09-24 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
| JP2023124147A Withdrawn JP2023159114A (ja) | 2012-08-24 | 2023-07-31 | 心房拡大又はリモデリングを特徴とする疾患を治療するためのｎｅｐ阻害剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9517226B2 (enExample) |
| EP (2) | EP3943084A1 (enExample) |
| JP (4) | JP6482462B2 (enExample) |
| KR (2) | KR102159601B1 (enExample) |
| CN (2) | CN104602711A (enExample) |
| AU (1) | AU2013304949C1 (enExample) |
| BR (1) | BR112015003067A2 (enExample) |
| CA (1) | CA2882771C (enExample) |
| CL (1) | CL2015000426A1 (enExample) |
| DK (1) | DK2887961T3 (enExample) |
| ES (1) | ES2879550T3 (enExample) |
| HU (1) | HUE054885T2 (enExample) |
| IL (1) | IL237114B (enExample) |
| MA (1) | MA37850A1 (enExample) |
| MX (1) | MX378867B (enExample) |
| NZ (1) | NZ704604A (enExample) |
| PH (1) | PH12015500375A1 (enExample) |
| PL (1) | PL2887961T3 (enExample) |
| PT (1) | PT2887961T (enExample) |
| RU (1) | RU2667643C2 (enExample) |
| SG (1) | SG11201500256UA (enExample) |
| SI (1) | SI2887961T1 (enExample) |
| TN (1) | TN2015000028A1 (enExample) |
| TW (1) | TWI634887B (enExample) |
| WO (1) | WO2014029848A1 (enExample) |
| ZA (1) | ZA201500262B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| MX378867B (es) | 2012-08-24 | 2025-03-11 | Novartis Ag | Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular. |
| HRP20200060T1 (hr) | 2013-08-26 | 2020-04-03 | Novartis Ag | Nova uporaba |
| EP3110449B1 (en) * | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
| EP2990800A1 (en) * | 2014-08-29 | 2016-03-02 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Neprilysin as heartfailure (HF) prognostic marker |
| HRP20230480T1 (hr) * | 2015-05-11 | 2023-07-21 | Novartis Ag | Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca |
| US20180140579A1 (en) | 2015-05-29 | 2018-05-24 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
| CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
| WO2017037577A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | New use |
| AU2017215530B2 (en) | 2016-02-03 | 2019-09-12 | Novartis Ag | Galenic formulations of organic compounds |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
| WO2019008485A1 (en) | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| KR20210032437A (ko) | 2018-08-23 | 2021-03-24 | 노파르티스 아게 | 심부전의 치료를 위한 신규한 약제학적 용도 |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| KR20210137520A (ko) | 2019-03-08 | 2021-11-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-36r 항체 제형 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3004206A1 (de) | 1980-02-06 | 1981-08-13 | Hoechst Ag, 6000 Frankfurt | Verfahren zur herstellung von 1-alkyl-1-phenylhydrazinen |
| DE3005674A1 (de) | 1980-02-15 | 1981-08-20 | Ruhr-Zink GmbH, 4354 Datteln | Verwendung einer blei-legierung fuer anoden bei der elektrolytischen gewinnung von zink |
| DE3010374A1 (de) | 1980-03-18 | 1981-10-08 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten |
| US4610816A (en) | 1980-12-18 | 1986-09-09 | Schering Corporation | Substituted dipeptides as inhibitors of enkephalinases |
| US4383527A (en) | 1981-02-20 | 1983-05-17 | Howmedica, Inc. | Device for guiding the insertion of surgical wires into bone tissue |
| EP0063662B1 (fr) | 1981-04-24 | 1986-01-02 | Jean Martin | Ensemble préfabriqué pour la réalisation d'ossature pour la construction |
| ZA84670B (en) | 1983-01-31 | 1985-09-25 | Merck & Co Inc | Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors |
| US4722810A (en) | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4749688A (en) | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4929641B1 (en) | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| US4740499A (en) | 1986-07-28 | 1988-04-26 | Monsanto Company | Method of enhancing the bioactivity of atrial peptides |
| GB8811873D0 (en) | 1988-05-19 | 1988-06-22 | Pfizer Ltd | Therapeutic agents |
| GB8812597D0 (en) | 1988-05-27 | 1988-06-29 | Pfizer Ltd | Therapeutic agents |
| GB2218983A (en) | 1988-05-27 | 1989-11-29 | Pfizer Ltd | Spiro-substituted glutaramides as diuretics |
| EP0361365A1 (en) | 1988-09-30 | 1990-04-04 | E.R. SQUIBB & SONS, INC. | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use |
| GB8903740D0 (en) | 1989-02-18 | 1989-04-05 | Pfizer Ltd | Therapeutic agents |
| ATE134624T1 (de) | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
| US5223516A (en) | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
| GB9103454D0 (en) | 1991-02-19 | 1991-04-03 | Pfizer Ltd | Therapeutic agents |
| US5294632A (en) | 1991-05-01 | 1994-03-15 | Ciba-Geigy Corporation | Phosphono/biaryl substituted dipetide derivatives |
| US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
| US5273990A (en) | 1992-09-03 | 1993-12-28 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives |
| GB9123353D0 (en) | 1991-11-04 | 1991-12-18 | Fujisawa Pharmaceutical Co | New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| WO1993010773A1 (en) | 1991-12-06 | 1993-06-10 | Schering-Plough S.P.A. | Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy |
| US5217996A (en) | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
| DE4233296C1 (de) | 1992-10-02 | 1994-03-31 | Heitland Und Petre Int Gmbh | Behälter für Kosmetikprodukte |
| WO1994015908A1 (fr) | 1993-01-14 | 1994-07-21 | Yoshitomi Pharmaceutical Industries, Ltd. | Derive de propionamide et son utilisation medicinale |
| JPH06234754A (ja) | 1993-02-10 | 1994-08-23 | Dai Ichi Seiyaku Co Ltd | 複素環式カルボン酸誘導体 |
| IT1266571B1 (it) | 1993-07-30 | 1997-01-09 | Zambon Spa | Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari |
| JP3576193B2 (ja) | 1993-12-03 | 2004-10-13 | 第一製薬株式会社 | ビフェニルメチル置換バレリルアミド誘導体 |
| US6201002B1 (en) | 1997-01-10 | 2001-03-13 | Merck & Co., Inc. | Method for reducing mortality with an angiotensin II antagonist |
| CA2472399C (en) * | 2002-01-17 | 2012-02-21 | Novartis Ag | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| RU2245162C2 (ru) * | 2003-01-04 | 2005-01-27 | Козлов Владимир Александрович | Способ терапии инфаркта миокарда |
| US20070054947A1 (en) | 2003-05-16 | 2007-03-08 | Cohn Jay N | Pharmaceutical composition comprising valsartan |
| MY146830A (en) | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| PL2295035T3 (pl) * | 2007-11-06 | 2016-11-30 | Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep) | |
| WO2012027237A1 (en) * | 2010-08-24 | 2012-03-01 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| MX378867B (es) | 2012-08-24 | 2025-03-11 | Novartis Ag | Inhibidores de la nep para el tratamiento de enfermedades caracterizadas por el ensanchamiento o remodelacion auricular. |
-
2013
- 2013-08-22 MX MX2015002432A patent/MX378867B/es unknown
- 2013-08-22 AU AU2013304949A patent/AU2013304949C1/en active Active
- 2013-08-22 EP EP21168346.1A patent/EP3943084A1/en not_active Withdrawn
- 2013-08-22 US US14/422,855 patent/US9517226B2/en active Active
- 2013-08-22 RU RU2015110240A patent/RU2667643C2/ru active
- 2013-08-22 PL PL13750725T patent/PL2887961T3/pl unknown
- 2013-08-22 KR KR1020157004112A patent/KR102159601B1/ko not_active Ceased
- 2013-08-22 EP EP13750725.7A patent/EP2887961B1/en not_active Revoked
- 2013-08-22 WO PCT/EP2013/067472 patent/WO2014029848A1/en not_active Ceased
- 2013-08-22 PT PT137507257T patent/PT2887961T/pt unknown
- 2013-08-22 MA MA37850A patent/MA37850A1/fr unknown
- 2013-08-22 ES ES13750725T patent/ES2879550T3/es active Active
- 2013-08-22 SG SG11201500256UA patent/SG11201500256UA/en unknown
- 2013-08-22 KR KR1020207026971A patent/KR20200111822A/ko not_active Ceased
- 2013-08-22 CA CA2882771A patent/CA2882771C/en active Active
- 2013-08-22 BR BR112015003067A patent/BR112015003067A2/pt not_active IP Right Cessation
- 2013-08-22 DK DK13750725.7T patent/DK2887961T3/da active
- 2013-08-22 JP JP2015527922A patent/JP6482462B2/ja active Active
- 2013-08-22 CN CN201380044470.1A patent/CN104602711A/zh active Pending
- 2013-08-22 NZ NZ704604A patent/NZ704604A/en unknown
- 2013-08-22 HU HUE13750725A patent/HUE054885T2/hu unknown
- 2013-08-22 CN CN201810388983.9A patent/CN108685889A/zh active Pending
- 2013-08-22 SI SI201331902T patent/SI2887961T1/sl unknown
- 2013-08-23 TW TW102130334A patent/TWI634887B/zh not_active IP Right Cessation
-
2015
- 2015-01-14 ZA ZA2015/00262A patent/ZA201500262B/en unknown
- 2015-01-19 TN TNP2015000028A patent/TN2015000028A1/fr unknown
- 2015-02-05 IL IL237114A patent/IL237114B/en active IP Right Grant
- 2015-02-20 PH PH12015500375A patent/PH12015500375A1/en unknown
- 2015-02-23 CL CL2015000426A patent/CL2015000426A1/es unknown
-
2016
- 2016-11-08 US US15/345,941 patent/US9937143B2/en active Active
-
2018
- 2018-03-06 US US15/912,701 patent/US11135192B2/en active Active
- 2018-12-05 JP JP2018228452A patent/JP7407508B2/ja active Active
-
2021
- 2021-09-24 JP JP2021155220A patent/JP2022020624A/ja active Pending
-
2023
- 2023-07-31 JP JP2023124147A patent/JP2023159114A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015526458A5 (enExample) | ||
| RU2015110240A (ru) | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия | |
| JP6309454B2 (ja) | 癌の併用処置 | |
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| JP2020529996A5 (enExample) | ||
| FI3661514T3 (fi) | Mavakamteeni käytettäväksi hypertrofisen kardiomyopatian hoidossa | |
| WO2016205695A1 (en) | Methods and compositions for treating herpesvirus induced conditions | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2010540519A5 (enExample) | ||
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2015522077A5 (enExample) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2019507786A5 (enExample) | ||
| JP2018529747A5 (enExample) | ||
| CN111132677A (zh) | 西尼莫德的给药方案 | |
| RU2017142589A (ru) | Композиции и способы лечения или предупреждения легочной гипертензии | |
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| JPWO2019246225A5 (enExample) | ||
| JPWO2023078333A5 (enExample) | ||
| JP2011157395A5 (enExample) | ||
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JP7356968B2 (ja) | 心血管疾患に有用な医薬 |